July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

such as cutaneous lupus erythematosus (CLE), is less well studied. An improved understanding of the metabolic pathways dysregulated in CLE may lead to novel treatment options, biomarkers and insights ...

Hypertrophic LE is a rare subset of chronic cutaneous LE and represents 2% of ... When the palms and soles are involved, hypertrophic lupus produces localized or partially diffuse keratoderma.

BACKGROUND: Nearly 10% of lupus erythematosus (LE ... terbinafine for a suspected dermatophytic infection developed a subacute cutaneous LE, within 7 weeks following terbinafine introduction.

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related ...

subacute cutaneous lupus erythematosus (SCLE), chronic cutaneous lupus erythematosus (CCLE), systemic lupus erythematosus. The drug candidate is a new biological entity (NBE) and a humanized ...

Living with lupus can significantly affect your mental health. This January we are honoring Mental Wellness Month by exploring the intersection of lupus and mental health with a four-part series of ...

Increased odds of atherosclerotic cardiovascular disease seen in association with cutaneous lupus and systemic lupus, but not psoriasis. HealthDay News — Cutaneous lupus erythematosus (CLE ...

WEDNESDAY, Jan. 15, 2025 (HealthDay News) -- Cutaneous lupus erythematosus (CLE) is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), similar to the risk seen in ...